Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVA-TTR
2024-515661-34-00Phase 4Authorised
- Sponsor
- Fundación de Investigación Biomédica Hospital Puerta de Hierro
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sacubitril + valsartan in amyloidotic transthyretin cardiomyopathy (ATTR-CM) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Fundación de Investigación Biomédica Hospital Puerta de Hierro. Primary endpoint: Change in left ventricular ejection fraction at 12 months. Planned start Feb 2025; status: authorised.
02
Drugs
sacubitril + valsartan
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2024-515661-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515661-34-00.